The predictive value of surrogate insulin resistance indices for T2DM complicated with metabolic syndrome: a retrospective study based on hospitalized patients in China
Frontiers in Endocrinology · 2026
DOI: 10.3389/fendo.2026.1782071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, 2026. Verfasst von Sixu Xin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Peking University International Hospital, Beijing, China. Hauptthemen laut MEDLINE: Metabolic Syndrome, Diabetes Mellitus, Type 2, Insulin Resistance, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To evaluate the predictive value of surrogate indices of insulin resistance (IR)- specifically, the triglyceride-glucose (TyG) index, the triglyceride glucose-body mass (TyG-BMI) index, and the triglyceride (TG) to high-density lipoprotein cholesterol (HDL-C) for metabolic syndrome (MetS) in patients with type 2 diabetes mellitus (T2DM).
Methods
A single-center, retrospective study was conducted involving 2409 T2DM patients. Based on the presence of MetS, participants were divided into a T2DM-MetS group (n=1,787) and a T2DM-only group (n=622). Logistic regression was used to analyze the influencing factors for T2DM complicated with MetS, and to compare the predictive value of the TyG index, the TyG-BMI index, and the TG/HDL-C ratio. A nomogram prediction model was constructed. The model’s discriminative ability, clinical utility, and calibration were evaluated using the receiver operating characteristic (ROC) curve, decision curve analysis (DCA), and a calibration curve, respectively.
Results
The multivariate logistic regression analysis model revealed that Sex, Wasit-to-hip ratio (WHR), fasting C-Peptide (FCP), 2-hour C-Peptide (2hCP), the TyG index, the TyG-BMI index, and the TG/HDL-C ratio were risk factors for T2DM complicated with MetS. The area under the curve (AUC) for the TyG index, the TyG-BMI index, and the TG/HDL-C ratio in predicting T2DM complicated with MetS were 0.809, 0.807, and 0.915, respectively. The prediction model was constructed using the TG/HDL-C ratio, Sex, WHR, and FCP. The model demonstrated that the C-index for predicting the presence of MetS in T2DM patients was 0.922 (95% CI: 0.909, 0.936). The DCA showed a maximum net benefit rate of 0.742.
Conclusions
The surrogate indices for IR (the TyG index, the TyG-BMI index, and the TG/HDL-C ratio) were risk factors for T2DM complicated with MetS, among which the TG/HDL-C ratio was the optimal predictor. The nomogram model constructed based on the TG/HDL-C ratio, Sex, WHR, and FCP demonstrated good predictive performance for T2DM complicated with MetS. This model shows good calibration and practicality, providing a valuable reference to aid in early identification and preventive strategies in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Peking University International Hospital, Beijing, China.
Zitieren
APA
Xin, S., Zhang, X., Zhao, X., & Sun, J. (2026). The predictive value of surrogate insulin resistance indices for T2DM complicated with metabolic syndrome: a retrospective study based on hospitalized patients in China. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2026.1782071
Vancouver
Xin S, Zhang X, Zhao X, Sun J. The predictive value of surrogate insulin resistance indices for T2DM complicated with metabolic syndrome: a retrospective study based on hospitalized patients in China. Frontiers in Endocrinology. 2026. doi:10.3389/fendo.2026.1782071
BibTeX
@article{Xin2026,
author = {Xin, Sixu and Zhang, Xiaomei and Zhao, Xin and Sun, Jianbin},
title = {The predictive value of surrogate insulin resistance indices for T2DM complicated with metabolic syndrome: a retrospective study based on hospitalized patients in China},
journal = {Frontiers in Endocrinology},
year = {2026},
doi = {10.3389/fendo.2026.1782071}
}
EUVIMED